Comparison results
| Results: Differences General | ✘Polymastia | ✘Tumors of the pineal gland | |||||||||||||
| Related research | Analogs | Analogs | |||||||||||||
| |||||||||||||||
| Distinctive symptoms | |||||||||||||||
| Register, to see more distinctive signs of diseases and studies | 100% | — | |||||||||||||
| Register, to see more distinctive signs of diseases and studies | — | 100% | |||||||||||||
| additional mammary gland | 60% | — | |||||||||||||
| hot feet | — | 85% | |||||||||||||
| hereditary breast cancer | 45% | — | |||||||||||||
| pineocytoma | — | 72% | |||||||||||||
| breast tumor | 32% | — | |||||||||||||
| hyperchromia | — | 69% | |||||||||||||
| mastitis | 30% | — | |||||||||||||
| tumors of the pineal gland | — | 67% | |||||||||||||
| involution of the mammary glands | 30% | — | |||||||||||||
| aggressive child | — | 64% | |||||||||||||
| pain gives in the groin | 30% | — | |||||||||||||
| leukocyturia | — | 57% | |||||||||||||
| history of chest surgery | 29% | — | |||||||||||||
| pineoblastoma | — | 56% | |||||||||||||
| pain in the armpit | 29% | — | |||||||||||||
| proteinuria | — | 51% | |||||||||||||
| intrauterine fetal development delay | 26% | — | |||||||||||||
| aggressive | — | 46% | |||||||||||||
| family history of cancer | 25% | — | |||||||||||||
| hot palms | — | 36% | |||||||||||||
| consequences of infection | 23% | — | |||||||||||||
| brain stem tumors | — | 36% | |||||||||||||
| solid tumors | 23% | — | |||||||||||||
| brain tumor | — | 35% | |||||||||||||
| pain in the groin area | 23% | — | |||||||||||||
| benign neoplasms | — | 34% | |||||||||||||
| breast cancer | 23% | — | |||||||||||||
| occlusive hydrocephalus | — | 28% | |||||||||||||
| inflammation | 22% | — | |||||||||||||
| insufficient convergence | — | 25% | |||||||||||||
| oncology relatives | 22% | — | |||||||||||||
| hydrocephalus | — | 25% | |||||||||||||
| decreased intelligence | 22% | — | |||||||||||||
| hearing loss | — | 23% | |||||||||||||
| open person | 21% | — | |||||||||||||
| pupil's reaction to light is sluggish | — | 23% | |||||||||||||
| mental retardation | 21% | — | |||||||||||||
| ophthalmoplegia | — | 21% | |||||||||||||
| painful appearance | 20% | — | |||||||||||||
| vascular tumor | — | 21% | |||||||||||||
| consequences of pregnancy | 19% | — | |||||||||||||
| subarachnoid hemorrhage | — | 21% | |||||||||||||
| not enough time | 19% | — | |||||||||||||
| metastatic brain tumors | — | 21% | |||||||||||||
| pain chest | 19% | — | |||||||||||||
| paralytic syndrome | — | 18% | |||||||||||||
| surgical infections | 18% | — | |||||||||||||
| rapid growth | — | 18% | |||||||||||||
| lags behind in the development | 18% | — | |||||||||||||
| loss of balance | — | 17% | |||||||||||||
| consequences of surgery | 17% | — | |||||||||||||
| the body is not his | — | 17% | |||||||||||||
| cancer in the anamnesis | 22% | 17% | |||||||||||||
| aneurysm | — | 17% | |||||||||||||
| metastases | 20% | 16% | |||||||||||||
| clear boundaries | — | 16% | |||||||||||||
| hearing impaired | — | 16% | |||||||||||||
| paralysis | — | 16% | |||||||||||||
| impaired coordination | — | 15% | |||||||||||||
| radiation damage | — | 15% | |||||||||||||
| paresis | — | 15% | |||||||||||||
| radiation therapy | — | 15% | |||||||||||||
| imbalance | — | 14% | |||||||||||||
| necrosis | — | 14% | |||||||||||||
| impaired arterial function | — | 13% | |||||||||||||
| oncology in the anamnesis | 20% | 27% | |||||||||||||
| cancer | 24% | 31% | |||||||||||||
| oncology | 22% | 28% | |||||||||||||
Instructions
Video 
- Introduce new diseases through 🔍 Search and input on the top panel using
- The table shows the most important distinguishing symptoms, tests and diagnoses related to the selected diseases.
- The higher the percentage, the more important this symptom is for the disease and vice versa. At 0%, we can say that this symptom never occurs in the disease.
- The list changes dynamically depending on the data of the current visit in the selection of therapy .
- Click on the percentageto see the suggestions from the original source.
- By using the service, you agree to user agreement.
